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Abbreviations 
ANOVA Analysis of variance 
APC  Antigen presenting cell 
BAL   Bronchoalveolar lavage 
BALF    Bronchoalveolar lavage fluid 
CAB   Chromotrop-anilinblue 
ELISA  Enzyme-linked immunosorbent assay 
ERK   Extracellular signal-regulated kinases 
FACS   Fluorescence-activated cell sorting 
FGF(1/2/3) Fibroblast growth factor 1/2/3 
FGFR(1/2/3) Fibroblast growth factor receptor 1/2/3 
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GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
HRP   Horseradish peroxidase 
IC50  Half-maximal inhibitory concentration 
IL-1(β)  Interleukin-1 (beta) 
IL-1Ra  Interleukin-1 receptor antagonist (protein) 
IL1RN  Interleukin-1 receptor antagonist (gene) 
IL-6   Interleukin-6 
IPF   Idiopathic pulmonary fibrosis 
KC   Keratinocyte chemoattractant 
MMP   Matrix metalloproteinase 
NHLF   Normal human lung fibroblasts 
PBS  Phosphate buffered saline 
PCR   Polymerase chain reaction 
PDGF BB Platelet-derived growth factor BB (homodimer) 
PDGF(α/β)  Platelet-derived growth factor (alpha/beta) 
PDGFR(α/β)  Platelet-derived growth factor receptor (alpha/beta) 
RTK   Receptor tyrosine kinase 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SMA   Smooth muscle actin 
TBS  Tris-buffered saline 
TGF-β  Transforming growth factor beta 
TIMP-1  Tissue inhibitor of metalloproteinase 
VEGF  Vascular endothelial growth factor 









The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the 
treatment of idiopathic pulmonary fibrosis (IPF). To explore its mode of action, nintedanib 
was tested in human lung fibroblasts and mouse models of lung fibrosis. Human lung 
fibroblasts expressing PDGF-receptor-α and -β were stimulated with PDGF-BB. Receptor 
activation was assessed by autophosphorylation and cell proliferation by bromodeoxyuridine 
incorporation. TGFβ-induced fibroblast to myofibroblast transformation was determined by 
αSMA mRNA analysis. Lung fibrosis was induced in mice by intratracheal bleomycin or silica 
particle administration. Nintedanib was administered qd by gavage at 30, 60 or 100 mg/kg. 
Preventive nintedanib treatment started on the day that bleomycin or silica was administered, 
therapeutic treatment at various times after the induction of lung fibrosis. Bleomycin caused 
increased macrophages and lymphocytes in the bronchoalveolar lavage (BAL) and elevated 
IL-1β, TIMP-1 and collagen in lung tissue. Histology revealed chronic inflammation and 
fibrosis. Silica-induced lung pathology additionally showed elevated BAL neutrophils, KC 
levels and granuloma formation. Nintedanib inhibited PDGF-receptor activation, fibroblast 
proliferation and fibroblast to myofibroblast transformation. Nintedanib significantly reduced 
BAL lymphocytes and neutrophils but not macrophages. Furthermore, IL-1β, KC, TIMP-1, 
and lung collagen were significantly reduced. Histological analysis showed significantly 
diminished lung inflammation, granuloma formation and fibrosis. The therapeutic effect was 
dependent on treatment start and duration. Nintedanib inhibited receptor tyrosine kinase 
activation and the proliferation and transformation of human lung fibroblasts and showed 
anti-fibrotic and anti-inflammatory activity in two animal models of pulmonary fibrosis. These 
results suggest that nintedanib may impact the progressive course of fibrotic lung diseases 




Idiopathic pulmonary fibrosis (IPF) is a progressive, severely debilitating disease with a high 
mortality rate (King, Jr., et al., 2011). Mean survival following diagnosis ranges from 2 to 3 
years (Raghu, et al., 2011). Even though IPF is considered rare, it is the most common 
idiopathic interstitial lung disease (ATS and ERS, 2002). The pathomechanisms that result in 
IPF are not fully understood. It has been hypothesized that injuries of the lung lead to 
destruction of epithelial alveolar cells, and that the resulting repair process is dysregulated, 
leading to the proliferation and migration of fibroblasts, transformation to myofibroblasts and 
excessive collagen deposition within the lung interstitium and alveolar space (Fernandez and 
Eickelberg, 2012). Progressive fibrosis with stiffening of the lungs leads to dyspnea and 
cough. The symptoms of IPF limit physical activity and reduce patients’ quality of life and 
independence (De, et al., 2001;Swigris, et al., 2005). Despite high medical need, the latest 
international guidelines for the management of IPF did not recommend any specific 
pharmacological treatments for the chronic treatment of IPF (Raghu, et al., 2011).  
Nintedanib (BIBF 1120) is a potent intracellular tyrosine kinase inhibitor targeting fibroblast 
growth factor receptor (FGFR)-1, -2 and -3, platelet derived growth factor receptor (PDGFR)α 
and β and vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3. Nintedanib also 
inhibits the Src family tyrosine kinases Lck and Lyn and Flt-3 (Hilberg, et al., 2008). The 
contribution of inhibition of specific kinases to the mode of action of nintedanib in IPF has not 
been clarified. However, distinct functions that may impact IPF pathology have been 
described for specific tyrosine kinases. FGFR1 is expressed on epithelial cells, endothelial 
cells, smooth muscle cells, myofibroblast-like cells and macrophages in the lungs of patients 
with IPF, and FGFR2 on smooth muscle cells, myofibroblast-like cells and neutrophils (Inoue, 
et al., 2002). FGF-2 stimulates proliferation of lung fibroblasts from patients with IPF (Hetzel, 
et al., 2005). In vivo abrogation of FGF signaling reduces bleomycin-induced pulmonary 
fibrosis and improves survival in bleomycin-treated mice (Yu, et al., 2012). PDGF is 
produced by alveolar macrophages and epithelial cells  (Antoniades, et al., 1990;Bonner, 
JPET #208223 
 
2004). PDGF is a potent mitogen for fibroblasts (Clark, et al., 1993) and appears to play an 
essential role in the expansion of myofibroblasts by stimulating proliferation, migration and 
survival. Elevated levels of PDGF have consistently been observed in the fibrotic lesions of 
various organs (Bonner, 2004). Myofibroblasts, when too active or too numerous, deposit 
excessive connective tissue products in the alveolar wall. The result is a distorted alveolar 
architecture with compromised gas exchange (Katzenstein and Myers, 1998;Kim, et al., 
2006;Raghu, et al., 2011). PDGFR-specific tyrosine kinase inhibitors reduce pulmonary 
fibrosis in animal models of lung fibrosis (Abdollahi, et al., 2005;Aono, et al., 2005;Li, et al., 
2009;Rice, et al., 1999;Vuorinen, et al., 2007).  
Vascular abnormalities are a common feature in interstitial lung diseases; however the roles 
of angiogenesis and VEGF signaling in IPF are unclear. It is controversial whether 
angiogenesis plays a key role in abnormal extracellular matrix remodeling and fibrosis in the 
lung (King, Jr., et al., 2011;Renzoni, 2004), and extensive temporal and spatial heterogeneity 
in angiogenesis has been observed in patients with IPF (Farkas and Kolb, 2011). However, 
experimental overexpression of VEGF in airways induces airway inflammation and 
remodeling with mucus metaplasia and sub-epithelial fibrosis (Lee, et al., 2011), and VEGF 
expression correlates with sub-epithelial fibrosis in patients with asthma (Chetta, et al., 
2005). Anti-VEGF gene therapy attenuates bleomycin-induced fibrosis in mice (Hamada, et 
al., 2005).  
The results of a Phase II trial of nintedanib (the TOMORROW trial) suggest that 12 months’ 
treatment with nintedanib, at a dose of 150 mg bid, slows decline in lung function, reduces 
acute exacerbations, and preserves quality of life in patients with IPF, and has an acceptable 
safety and tolerability profile  (Richeldi, et al., 2011). Two Phase III trials of nintedanib in 
patients with IPF have recently been completed. 
The rationale for the in vitro and in vivo studies presented here was to elucidate the potential 
mode of action of nintedanib in fibrotic lung diseases like IPF. In this report, we describe anti-
inflammatory and anti-fibrotic properties of nintedanib. We provide the cellular kinase profile 
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of nintedanib and assess effects on the proliferation of fibroblasts. Further, we show that 




Material and methods 
Cellular BA/F3 tyrosine kinase assay 
The cellular tyrosine kinase assay was performed by Carna Biosciences Inc., Kobe, Japan. 
The assay principle builds on the work of Daley & Baltimore (Daley, et al., 1987). Briefly, the 
proliferation and survival of BA/F3 cells is usually dependent on IL-3. BA/F3 cells were 
transformed by inducing target kinase dimerization via viral vectors. Proliferation and survival 
were engineered to become dependent upon maintenance of activity of an introduced 
specific tyrosine kinase. Inhibition of this tyrosine kinase results in a directly proportional 
decrease in cell viability, which, as each cell is modified to produce a uniform quantity of 
luciferase, results in decreased luminescence. Nintedanib (methyl (3Z)-3-[({4-[N-methyl-2-(4-
methylpiperazin-1-yl)acetamido]phenyl}amino)(phenyl) methylidene]-2-oxo-2,3-dihydro-1H-
indole-6-carboxylate ethane sulfonate salt) was provided by Boehringer Ingelheim Pharma 
GmbH & Co. KG, Biberach, Germany and was tested at concentrations of 10 nmol/L – 1000 
nmol/L on FGFR1-4, PDGFRα/β, VEGFR 1-3, Flt-3, Lck, Lyn and Src. 
Inhibition of receptor tyrosine kinase (RTK) phosphorylation and proliferation of 
normal human lung fibroblasts 
Normal human lung fibroblasts (NHLF) (No. AG CC-2512, Lonza, Basel, Switzerland) at 
passage 6 to 8 were stimulated with recombinant human PDGF-BB (220-BB, R&D Systems, 
GmbH, Wiesbaden-Nordenstadt, Germany), b-FGF (234-FSE, R&D Systems), or VEGF 
(293-VE, R&D Systems). Stimulation of the respective receptor phosphorylation was 
explored by Western blot analysis (data not shown) and ELISA. Fibroblast proliferation was 
assessed by BrdU incorporation. Because only PDGF-BB stimulation led to a statistically 
significant increase in RTK phosphorylation of PDGFRα and PDGFRβ and fibroblast 
proliferation, the pharmacology of nintedanib was only explored on these two receptors. 
RTK phosphorylation: Briefly, 24 h after seeding 15,000 NHLF/well with 100 µL/well FBM 
(No: CC-3131, Lonza.) the cells were grown to about 90% confluence. Cells were starved for 
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24 h and incubated with nintedanib at 0.128 nmol/L – 10 µmol/L for 30 min. Subsequently, 
the cells were stimulated with PDGF-BB (50 ng/mL) for 8 min. After lysis the amount of 
phosphorylated receptor was determined by human phospho-PDGFRα and β ELISA (DuoSet 
IC, R&D Systems, DYC2114-5 and DYC1767-5, respectively).  
Proliferation: 24 h after seeding 2000 NHLF/well cells were grown to about 50% confluence. 
Cells were starved in FBM medium containing insulin for 24 h, then incubated with nintedanib 
at 0.3 – 1000 nmol/L for 30 min and stimulated with PDGF-BB at 50 ng/mL for 72 h. 
Subsequently, BrdU incorporation was determined after 18 h according to manufacturers’ 
instruction (Assay no. 11647229001, Roche, Basel, Switzerland) to determine inhibition of 
proliferation. 
TGF-β-stimulated fibroblast to myofibroblast transformation 
The activity of nintedanib on transforming growth factor (TGF)-β2-induced α-smooth muscle 
actin (SMA) gene expression was explored in primary fibroblast cell lines according to 
Chaudhary et al. (Chaudhary, et al., 2007).  Briefly, human lung fibroblasts from three 
patients (mixed sex) with lung fibrosis were incubated with TGF-β2 in the presence of 
nintedanib at concentrations ranging from 30 to 3000 nmol/L. After incubation for 72 h, the 
gene expression levels of α-SMA were determined by quantitative real-time PCR and 
normalized relative to endogenous 18S RNA. Data are presented as a percentage of gene 
expression compared with vehicle alone. 
 
Inhibition of RTK activation in vivo 
Eight- to ten-week-old C57BL/6 mice (Charles River, Kissleg, Germany) were housed under 
a 12-h light-dark cycle and received food and water ad libitum. Animal experimentation was 
conducted in accordance with German national guidelines and regulations. An aqueous 
solution of nintedanib was prepared by heating to 50°C while stirring. Nintedanib was 
administered by gavage at 3, 10, 30 and 100 mg/kg (n = 3 per group); 110 minutes later, 
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animals were anesthetized with 60 mg/kg pentobarbital-sodium and  2.5 mg/kg xylazin i.p.. 
Five minutes later, recombinant mouse PDGF-BB (ProSpec-Tany TechnoGene Ltd., Ness-
Ziona, Israel, 50 µg/animal) or vehicle was administered intratracheally. 5 to 30 min after 
PDGF-BB stimulation, whole lungs were excised. 
Western blot analysis of lung tissue 
Frozen lungs were lysed in 1 mL lysis buffer (50 mmol/L Tris-HCl, pH 7.6, 137 mmol/L 
sodium chloride, 10% glycerol, 0.1% Igepal, 0.1% SDS, 50 mmol/L sodium fluoride, 1 
mmol/L sodium orthovanadate) containing protease inhibitor cocktail (Thermo Fisher 
Scientific, Rockford, IL) using an Ultrathurrax (IKA, Staufen, Germany). Lysates were cleared 
by centrifugation before total protein determination with the BCA protein assay (Thermo 
Fisher Scientific GmbH). SDS PAGE and Western blotting were performed following a 
standard procedure using the Novex NuPAGE system (Life Technologies GmbH, Darmstadt, 
Germany). Following this, separation proteins were transferred to a PVDF membrane 
(Millipore, Billerica, MA, USA) in a wet blotting system (Bio-Rad, Hercules, CA, USA). 
Afterwards membranes were blocked and then probed with antibodies directed against 
GAPDH, PDGFRβ, phosphorylated PDGFRαβ (Tyr849/Tyr857), phosphorylated ERK1/2 
(Thr202/Tyr204), phosphorylated AKT (Ser473) (all Cell Signaling Technologies, Danvers, 
MA, USA) and PDGFRα (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The membranes 
were then washed in TBS-T followed by incubation with HRP-conjugated secondary 
antibodies (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Immunoreactive 
bands were detected by addition of an enhanced chemiluminescence substrate (Perkin 
Elmer, Waltham, MA, USA). The relative signal intensity of each band was determined with 
the AIDA image analysis software (Raytest) and corrected to the signal intensity of the 
loading control, GAPDH. 
Bleomycin- and silica-induced lung fibrosis in mice 
Eight-week-old female C57BL/6 mice (Janvier, Le Genest Saint Isle, France) were kept in 
groups of five. Animals had access to water and food ad libitum. All animal experiments were 
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conducted according to the French Government’s ethical and animal experiment regulations 
and the protocols were approved by the Regional Ethics committee (CL2007-021). 
Nintedanib was administered qd by gavage at 30, 60, or 100 mg/kg/day. Administration 
volume was 10 mL/kg body weight. Control animals received vehicle only. Depending on the 
model, animals received a single dose of bleomycin (clinical grade, Bleomycine Bellon, 
Sanofi-Aventis, France 1, mg = 1000 IU) at 3 mg/kg or silica particles at 2.5 mg/mouse by 
intranasal instillation as described before (Gasse, et al., 2007;Lo, et al., 2010). Controls 
received the respective saline solution by intranasal instillation. 
The study settings and drug treatment protocols are shown in Table 1. Briefly, in the 
preventive studies, nintedanib treatment started on the day of bleomycin or silica 
administration. In the therapeutic studies, nintedanib treatment started after the induction of 
lung fibrosis when the initial lung injury and inflammation were already abating. In each 
treatment group, 10 animals were included.  All analyses were performed on the last day of 
the experiment. Lung function was analyzed in the bleomycin study only. For invasive 
measurement of airway resistance and dynamic lung compliance with a plethysmograph 
(Buxco, London, UK), mice were anesthetized by intra-peritoneal injection of a solution 
containing ketamine/xylazine. Lung function testing was done with half the animals (n=5 per 
group). 
Mice were euthanized at the end of the experiment (Table 1). Total cell and differential cell 
counts were determined in the bronchoalveolar lavage fluid (BALF), total lung collagen was 
determined in lung tissue by means of the Sircol assay, and IL-1β, IL-6, KC and TIMP-1 were 
determined in lung homogenates. Details of the methods were according to Gasse et al. 
(Gasse, et al., 2007). 
 
After BAL and lung perfusion, the large lobe was fixed in 4% buffered formaldehyde and 
sections of 3 μm were stained with H&E or Chromotrope Aniline Blue. The severity of the 
morphological changes (infiltration by neutrophils and mononuclear cells and destruction and 
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thickening of the alveolar septae, and fibrosis and granuloma formation) were assessed 
semi-quantitatively using a score of 0–5 by two independent observers blinded to the 
treatments. 
Statistics 
All data are presented as mean ± S.E.M. of n animals. Statistical differences between groups 
were analyzed by one-way ANOVA with subsequent Dunnett`s multiple comparison test for 
all parametric data and Kruscal-Wallis test followed by Dunn's multiple comparison test for 
non-parametric data (GraphPad Software Inc., GraphPad Prism 5.04, La Jolla, CA). 





Inhibitory activity of nintedanib on RTKs in a cellular BA/F3 assay 
Nintedanib inhibited FGFR1-4, PDGFRα/β, VEGFR 1-3, FLT-3, LCK, LYN and SRC, in a 
dose-dependent manner in BA/F3 cells engineered to be proliferation-dependent on a single 
RTK. IC50 values for nintedanib are shown in Table 2.  
Effect of nintedanib on PDGF-BB-induced PDGFRα and β phosphorylation and 
proliferation of NHLF 
Nintedanib inhibited PDGF-BB-stimulated PDGFRα and β phosphorylation in a 
concentration-dependent manner with IC50 values of 22 nmol/L and and 39 nmol/L, 
respectively (Fig. 1). 
Nintedanib inhibited proliferation of PDGF-BB-stimulated fibroblasts with an IC50 value of 64 
nmol/L. Complete inhibition of PDGFRαand β phosphorylation led to 70% inhibition of 
fibroblast proliferation (Fig.1). 
Effect of nintedanib on TGF-β-stimulated fibroblast to myofibroblast differentiation 
Nintedanib inhibited TGF-β-stimulated fibroblast to myofibroblast differentiation as detected 
by αSMA gene expression in human fibroblasts from patients with IPF with an IC50 of 144 
nmol/L (data not shown). 
Effect of nintedanib on PDGFR phosphorylation in mouse lungs 
PDGFRα and β expression remained quite stable 5 to 30 min after PDGF stimulation (Suppl. 
Fig. 1). Maximum activation of the PDGFR detected by receptor phosphorylation was noted 5 
min after stimulation with PDGF-BB (Suppl. Fig. 1) and maximum downstream signaling of P-
AKT and P-ERK was detected at 15 min (Suppl. Fig. 1). 
To explore the efficacy of nintedanib to inhibit PDGFR phosphorylation as a marker of 
receptor activation, nintedanib was dosed orally in mice and 2h later, PDGFR was stimulated 
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by PDGF-BB. Nintedanib significantly inhibited PDGFR phosphorylation determined 5 min 
after PDGF stimulation in a dose-dependent manner (Fig. 2A and B). Downstream signaling 
of P-AKT and P-ERK was also diminished in a dose-dependent manner (Fig. 2A and Suppl. 
Fig. 2). The expression of PDGFRα and β was slightly elevated at higher doses of nintedanib 
5 min after PDGF-BB stimulation (Suppl. Fig. 2). 
Effect of nintedanib on pulmonary inflammation and fibrosis in a mouse model of 
bleomycin-induced lung injury and fibrosis 
A single intranasal administration of bleomycin was well tolerated and not associated with 
clinical adverse effects except for an initial loss of body weight of about 5% in the preventive 
study and a more sustained loss of up to 10% of body weight, reaching its maximum 
between day 9 and 11, in the therapeutic study.  Bleomycin administration caused a 
significant increase in lung weight at day 14 in the preventive study (vehicle control, 0.24 ± 
0.010 g compared to bleomycin control, 0.32 ± 0.013 g, P<0.01) and at day 21 in the 
therapeutic study (vehicle control, 0.28 ± 0.014 g compared to bleomycin control, 0.41 ± 
0.023 g, P<0.001). Neither airway resistance nor lung compliance was significantly changed 
by bleomycin administration at day 14 compared to the vehicle-treated controls (data not 
shown). In contrast, at day 21 bleomycin administration led to an increase in airway 
resistance (2.8 ± 0.49 cmH2O/mL*s, P<0.05) and a decrease in lung compliance (0.013 ± 
0.0028 mL/cmH2O, P<0.05) compared to vehicle-treated animals (1.39 ± 0.059 cmH2O/mL*s 
and 0.024 ± 0.0012 mL/cmH2O, respectively). Nintedanib treatment did not influence lung 
weight or lung function. 
Regardless of whether it was analyzed after 14 days or 21 days, bleomycin administration 
caused a similar significant increase in total cells (Fig. 3A and 4A), macrophages (Fig. 3B 
and 4B) and lymphocytes (Fig. 3C and 4C) measured in the BALF, while neutrophils were 
not detectable in the BALF (data not shown). Nintedanib significantly reduced lymphocyte 
counts in the preventive study at doses of 30 and 60 mg/kg (Fig. 3C, P<0.001) and in the 
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therapeutic study only at a dose of 60 mg/kg (Fig. 4C, P<0.01) but had no effect on total cell 
(Fig. 3A and 4A) or macrophage counts (Fig. 3B and 4B). 
Bleomycin administration significantly increased IL-1β (Fig. 3D and 4D) and TIMP-1 
concentrations (Fig. 3F and 4F) determined in lung tissue homogenates compared to 
controls. The increase in IL-1β was similar at day 14 (Fig. 3D) and day 21 (Fig. 4D). TIMP-1 
concentration further increased 1.9-fold between day 14 and day 21 (Fig. 3F and 4F, 
respectively). IL-1β was normalised by nintedanib in the preventive study (Fig. 3D) and 
significantly reduced at a dose of 60 mg/kg in the therapeutic study (P<0.05, Fig. 4D). 
Nintedanib reduced TIMP-1 at doses of 30 and 60 mg/kg (Fig. 3F, P<0.001) in the preventive 
study and at a dose of 60 mg/kg (P<0.05) in the therapeutic study (Fig. 4F). KC 
concentrations were not changed (Fig. 3E and 4E). 
Bleomycin administration significantly elevated total collagen concentration in lung tissue 
compared to controls to a similar extent at day 14 and day 21 (Fig. 3G and 4G). Significantly 
elevated semi-quantitative histology scores indicated inflammation (Fig. 3H and 5B) and 
fibrosis (Fig. 3I and 6B) at day 14 after bleomycin administration, which was slightly 
increased at day 21 in the therapeutic study (Fig. 4H, 5F, 4I and 6F). Nintedanib significantly 
reduced total lung collagen (Fig. 3G), inflammation (Fig. 3H, 5C and D) and fibrosis (Fig. 3I, 
6C and 6D) in the preventive study (P<0.01, p<0.01 and p<0.05, respectively). In the 
therapeutic study, the efficacy of nintedanib was slightly reduced (Fig. 4G, 4H) except the 
significant reduction of the fibrotic score (Fig. 4I, 6G and 6H) (P<0.05 and P<0.01, 
respectively).  
Effect of nintedanib on pulmonary inflammation, granuloma formation and fibrosis in a 
mouse model of silica-induced lung injury and fibrosis 
Silica administration was also well tolerated and not associated with any clinical adverse 
effects in mice. Silica administration caused a similar significant increase in lung weight in 
the preventive study (vehicle control, 0.30 ± 0.037 g compared to silica control, 0.35 ± 0.029 
g, P<0.01) and in the therapeutic study (vehicle control, 0.29 ± 0.034 g compared to silica 
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control, 0.36 ± 0.035 g, P<0.01). In the preventive study, nintedanib at a dose of 100 mg/kg 
reduced the silica-induced increase in lung weight by 44%, but this did not reach statistical 
significance. However, in the therapeutic study, silica-induced lung weight increase was 
significantly reduced by 74% at a dose of 30 mg/kg (P<0.01) and by 86% at a dose of 100 
mg/kg (P<0.01) if nintedanib treatment was started at day 10. If nintedanib treatment was 
started at day 20, reductions of 32% at a dose of 30 mg/kg and 43% at a dose of 100 mg/kg 
were detected (which did not reach statistical significance). 
In both the preventive and the therapeutic study, silica administration caused significant 
increases in total cells (Fig. 7A and 8A), macrophages (Fig. 7B and 8B), lymphocytes (Fig. 
7C and 8C) and neutrophils (Fig. 7D and 8D) measured in the BALF (P<0.001 for all cell 
types compared to negative control). Similar to the bleomycin study, nintedanib reduced 
silica-induced elevation in lymphocyte counts at a dose of 30 mg/kg (Fig. 7C, P<0.01) in the 
preventive study, but not total cell counts (Fig. 7A) or macrophages (Fig. 7B). Neutrophil 
counts were reduced significantly by nintedanib at doses of 30 and 100 mg/kg (Fig. 7D, 
P<0.01). In the therapeutic study, the significant reduction by nintedanib of lymphocyte count 
was dependent on dose and start of treatment (Fig. 8C). Higher dose, earlier start of 
treatment or longer treatment period provided better efficacy. Nintedanib reduced silica-
induced neutrophil invasion, but only if treatment was started at day 10 (Fig. 8D, P<0.001). 
Silica administration significantly increased IL-1β (Fig. 7E and 8E) KC (Fig. 7F and 8F) and 
TIMP-1 concentrations (Fig. 7G and 8H) determined in lung tissue homogenates to similar 
extents in both studies compared to saline-treated control lungs (P<0.001 for all mediators). 
IL-6 concentration was only significantly increased in the therapeutic study (Fig. 8G, P<0.01). 
In the preventive study, nintedanib significantly reduced IL-1β (Fig. 7E), KC (Fig. 7F) and 
TIMP-1 (Fig. 7G) concentrations independent of dose. In the preventive studies, nintedanib 
reduced IL-1β (Fig. 8E), KC (Fig. 8F), IL-6 (Fig. 8G) and TIMP-1 (Fig. 8H) if treatment was 
started at day 10, but not if treatment was started at day 20. 
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Silica administration slightly but significantly elevated total collagen concentration in lung 
tissue compared to saline-treated controls in both studies (Fig. 7H and 8I). Semi-quantitative 
analysis of the histology showed that silica administration led to elevated histology scores 
indicating inflammation (Fig. 7I and 8J), granuloma formation (Fig. 7J and 8K) and fibrosis 
(Fig. 7K and 8L) in the lungs. Representative histology micrographs are shown as 
supplementary Figures 3 and 4. Total lung collagen (Fig. 7H), lung inflammation (Fig. 7I), 
granuloma formation (Fig. 7J) and lung fibrosis (Fig. 7K) were significantly reduced by 
nintedanib in the preventive study. In the therapeutic study, significant reduction of the 
pathology by nintedanib was limited to total lung collagen at a dose of 30 mg/kg (P<0.05, Fig. 
8I), granuloma formation at a dose of 100 mg/kg (P<0.05, Fig. 8K) and lung fibrosis at doses 
of 30 and 100mg/kg (P<0.05, Fig. 8L) if treatment was started at day 10, but not if treatment 





To improve understanding of the mode of action of nintedanib in fibrotic lung diseases such 
as IPF, this study explored the inhibitory activity of nintedanib in cellular assays specific for 
selected tyrosine kinases, in human primary fibroblasts, and in two animal models of 
pulmonary fibrosis. 
A cellular BA/F3 assay confirmed the potent inhibitory activity of nintedanib on PDGFRα and 
β, VEGFR-2 and -3, and Lck and Lyn and its lower potency on FGFR-3 and 4, as reported in 
in vitro kinase assays (Hilberg, et al., 2008). Differences in IC50 values between the cellular 
BA/F3 assay and the in vitro assay were found for FGFR-1 and -2 and for VEGFR-1, with the 
cellular BA/F3 assay showing lower potency for nintedanib. Since BA/F3 cells are artificially 
engineered cells, these results can only be taken as a first indication of cellular activity. 
Compared with the cellular assays in endothelial cells, pericytes and vascular smooth muscle 
cells described by Hilberg (Hilberg, et al., 2008) the IC50 values are in concordance. More 
important insights were obtained with human lung fibroblasts stimulated with PDGF-BB. 
PDGF-BB stimulates PDGFRα and β causing αα and ββ homodimerization or αβ 
heterodimerization (Heldin, et al., 2002) and autophosphorylation of the receptor, which 
leads to stimulation of fibroblast proliferation (Hetzel, et al., 2005). We demonstrated that 
nintedanib inhibited PDGFRα and β phosphorylation and proliferation of human lung 
fibroblasts, an observation that is relevant to the pathology of IPF (Gunther, et al., 2012). The 
potency of nintedanib was quite similar on all the cellular systems tested, with IC50 values 
ranging from 22 to 64 nmol/L. However, complete inhibition of PDGFRα and β 
phosphorylation led to only 70% inhibition of fibroblast proliferation, indicating that a 
proportion of fibroblast proliferation is PDGFR-independent. Nintedanib also inhibited TGFβ-
induced fibroblast to myofibroblast differentiation, but only at higher concentrations (IC50 = 
144 nmol/L).  
To show that nintedanib exerts similar effects on PDGFR activation in vitro and in vivo, we 
demonstrated that nintedanib dose-dependently inhibited PDGFR phosphorylation and 
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downstream signaling via P-AKT and P-ERK in mouse lung tissue after oral dosing. Zhuo et 
al. (Zhuo, et al., 2004) demonstrated that PDGFRα phosphorylation was greater in 
bleomycin-treated mouse lungs compared with control lungs. Hence, it can be assumed that 
at least the proliferation of lung fibroblasts activated by PDGF/PDGFR interaction in mice is 
diminished in vivo by the nintedanib doses administered in the bleomycin- and probably in 
the silica-induced lung fibrosis studies.  
The in vivo experiments revealed that nintedanib exerted anti-fibrotic activity, as shown by 
reduced fibrosis in the histological analysis and by diminished lung collagen, reflecting 
reduced extracellular matrix production and/or deposition. We also found that TIMP-1, a key 
factor in the fibrogenic response to bleomycin in mice, (Manoury, et al., 2006) was 
significantly reduced by nintedanib in mouse lung tissue. In general, the anti-fibrotic activity 
of nintedanib was similar in the preventive and therapeutic studies of the silica-induced and 
bleomycin-induced fibrosis models except that there was reduced inhibition of TIMP-1 and 
total lung collagen at a dose of 30 mg/kg in the therapeutic bleomycin study and no inhibitory 
activity in the therapeutic silica model if nintedanib treatment was started at day 20. Either 
the late treatment start or the short treatment duration or both could be responsible for the 
observed reduction in anti-fibrotic activity. 
Nintedanib exerted anti-inflammatory activity, demonstrated by reduced lymphocyte and 
neutrophil counts in the BALF, diminished IL-1β and KC concentrations in lung 
homogenates, and reduced inflammation and granuloma formation in the histology analysis. 
In general, the anti-inflammatory activity of nintedanib was weaker in the therapeutic studies 
than in the preventive studies. This might be related to the fact that in the therapeutic studies, 
inflammation had peaked before nintedanib treatment was started. Reduction in BALF 
lymphocyte count seems to be the parameter most sensitive to nintedanib treatment: even 
though treatment was started late (at day 20) in the therapeutic silica study, nintedanib 
significantly reduced BALF lymphocytes. 
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Bleomycin-induced deterioratation in lung function was not influenced by nintedanib in the 
course of the experiments. This might be related to the relatively short treatment period of 14 
days in the preventive as well as in the therapeutic part of the bleomycin study. 
The strong and consistent inhibitory activity of nintedanib on IL-1β is an interesting finding. 
An imbalance of the IL-1 receptor antagonist (IL-1Ra) / IL-1β ratio, resulting in increased IL-
1β activity, has been reported in BALF macrophages from patients with IPF (Mikuniya, et al., 
1997).  Polymorphisms in IL1RN influence IL-1Ra mRNA expression, suggesting that lower 
levels of IL-1Ra predispose to developing IPF (Korthagen, et al., 2012). IL-1β is a well-known 
pro-inflammatory cytokine produced by macrophages of IPF patients (Zhang, et al., 1993). 
IL-1β was shown to have an important role in driving the development of fibrosis (Wilson, et 
al., 2010). The inhibition of IL-1β by nintedanib may help to dampen the pro-fibrotic milieu in 
the lung.   
A further interesting finding is the significant inhibition of TIMP-1 by nintedanib. TIMP-1 
inhibits many MMPs including MMP-1 (also known as collagenase-1) which is capable of 
degrading type I and II fibrilar collagens (Pardo and Selman, 2012). TIMP-1 expression has 
been found to be elevated in interstitial macrophages (Selman, et al., 2000), fibroblasts 
(Ramos, et al., 2001) and sputum (Beeh, et al., 2003) from patients with IPF. Thus the 
reduction in lung collagen produced by nintedanib might be at least partly attributable to its 
inhibitory activity on TIMP-1.  
Although in this study, only the inhibitory activity of nintedanib on PDGFR was explored in 
vitro, it is likely that inhibition of other tyrosine kinases contributes to the efficacy of 
nintedanib in vivo. According to Hilberg et al, (Hilberg, et al., 2008) exposure in mice after 
oral administration of 60 and 100 mg/kg nintedanib is sufficient to inhibit FGFRs, VEGFRs, 
Lck, Src and Flt-3 in the animal experiments presented here. The integrated anti-fibrotic and 
anti-inflammatory activity of nintedanib might be dependent on its inhibitory activity on 
multiple kinases. It is well documented that the PDGF/PDGFR signaling cascade is 
implicated in the development of pulmonary fibrosis (Bonner, 2004) but inhibition of FGFRs 
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might also have a role in the in vivo efficacy of nintedanib. Enhanced FGF levels, as well as 
increased expression of FGFR1 on epithelial, endothelial, and smooth muscle 
cell/myofibroblast-like cells and increased expression of FGFR2 on interstitial cells, have 
been detected in the lungs of patients with IPF (Inoue, et al., 2002). In vivo abrogation of 
FGF signaling has been shown to reduce bleomycin-induced pulmonary fibrosis and improve 
survival in bleomycin-treated mice (Yu, et al., 2012). The role of VEGF in IPF remains to be 
further explored but experimental evidence in rats suggests that inhibition of VEGFR may 
reduce fibrosis (Hamada, et al., 2005).  No specific role in the pathology of IPF has been 
described for Lck, Src and Flt-3. However, anti-inflammatory effects of nintedanib could 
potentially be partly attributable to its inhibitory activity on these tyrosine kinases (Das, et al., 
2006).  
No animal model is available resembling the exact pathology and chronicity of human IPF. In 
our attempt to elucidate the mode of action of nintedanib, inhibitory activity was explored in 
two well-described animal models of lung inflammation and fibrosis: the bleomycin-induced 
(Gasse, et al., 2007) and the silica-induced model (Lo, et al., 2010).   Both these models 
reflect at least some aspects of the pathology seen in patients with IPF.  When designing our 
studies, we followed the recommendations of Moeller et al. (Moeller, et al., 2008) in that all 
potential anti-fibrotic compounds should be evaluated in the phase of established fibrosis, 
rather than in the early period of bleomycin-induced inflammation, for assessment of 
antifibrotic properties.  
Both models show similarities but also differences in lung pathology. The bleomycin model is 
reported to show initial lung injury with strong but transient neutrophilic inflammation 
subsequently leading to lung fibrosis (Izbicki, et al., 2002). Bleomycin is metabolised in the 
lung, leading to a decrease in neutrophilic inflammation and a fibrotic response that 
spontaneously resolves after 2-3 months (Walters and Kleeberger, 2008). In the silica model, 
the stimulating crystals are not cleared from the lung, leading to ongoing inflammation, 
granuloma formation and progressive fibrosis (Callis, et al., 1985; Brass, et al., 2012). In our 
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study, lung inflammation and fibrotic score were quite similar in both models except for the 
strong neutrophilic inflammation and granuloma formation only detected in the silica-treated 
lungs and the stronger increase in lung weight in the bleomycin-treated lungs, which might 
be related to stronger matrix deposition indicated by the higher lung collagen increase. The 
consistent inhibitory effects shown by nintedanib in both animal models suggest that the anti-
fibrotic activity demonstrated in this study is an intrinsic feature of nintedanib and not only an 
indirect activity caused by suppressing the initial inflammatory response.  
In summary, we have shown that nintedanib inhibits RTK activation and proliferation and 
transformation of human lung fibroblasts. In vivo nintedanib showed consistent anti-fibrotic 
and anti-inflammatory activity in two animal models that reflect aspects of pulmonary fibrotic 
diseases. We propose that the anti-fibrotic and anti-inflammatory activities demonstrated in 
this study are likely aspects of the mode of action of nintedanib in fibrotic lung diseases. The 
inhibitory activity of nintedanib on lung fibrosis in the therapeutic studies raises the hope that 
nintedanib might reduce disease progression in patients with lung fibrosis. The anti-fibrotic 
and anti-inflammatory activity of nintedanib may impact the clinical course of pulmonary 
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Figure 1. Nintedanib inhibits PDGF-BB-stimulated PDGFRα and β phosphorylation and 
proliferation of human lung fibroblasts. Human lung fibroblasts were incubated with 
nintedanib at different concentrations and stimulated with PDGF-BB (50 ng/mL). PDGFRα 
and β phosphorylation was determined by ELISA specific for the phosphorylated receptors. 
Proliferation was determined by BrdU incorporation. Concentration–dependent inhibition of 
PDGFRα ( ) and β () autophosphorylation and fibroblast proliferation () is presented as 
mean ± SEM (n = 3 experiments). 
Figure 2. Nintedanib inhibits PDGF-BB stimulated PDGFR phosphorylation in mouse lung 
tissue. C57BL/6 mice received vehicle or 100, 30, 10 and 3 mg/kg of nintedanib by gavage (n 
= 3 per group). Two hours after compound dosing, PDGF-BB (50 µg) was intratracheally 
instilled to induce PDGF receptor phosphorylation. Five minutes later, the animals were 
euthanized and total lungs were excised, lysed and used for Western blot analysis to detect 
total and phosphorylated PDGF receptors, as well as phosphorylation of the downstream 
signaling molecules AKT and ERK1/2 by specific antibodies. GAPDH was used as a control. 
One representative Western blot showing 1 animal from each group is depicted for each 
antibody analyzed (A). The relative signal intensity of the phosphorylated PDGFRαβ bands 
was evaluated by densitometry and corrected by the intensity of the GAPDH control. Data 
are presented as mean ± S.E.M of 3 animals per group. (B). Statistical analysis was 
performed in Prism Graph Pad using one-way ANOVA with subsequent Dunnett's multiple 
comparison test *P < 0.05; **P < 0.01. 
Figure 3. Preventive nintedanib treatment reduces bleomycin-induced lung inflammation and 
fibrosis. C57Bl/6 mice received an intranasal instillation of NaCl or bleomycin 3 mg/kg. 
Nintedanib was administered qd by gavage at 30 and 60 mg/kg for 14 days. Analyses were 
performed at day 14. BAL cell differentiation is expressed as cells per mouse lung. A, total 
cell count, B, macrophages, C, lymphocytes. Mediator concentrations in whole lung 
homogenates were determined by ELISA. D, interleukin-1 beta (IL-1β), E, chemokine (C-X-C 
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motif) ligand 1/keratinocyte chemoattractant (KC), F, tissue inhibitor of metalloproteinase-1 
(TIMP-1). Total lung collagen was determined by sircol assay in lung homogenate (G). 
Hematoxylin & eosin and chromotrop-anilinblue (CAB) trichrome stained slices of the left 
lung were semi-quantitatively scored for inflammation (H) and fibrosis (I), respectively. All 
groups (n=10 per group) were compared versus bleomycin-treated control animals by 
ANOVA followed by Dunnett's multiple comparison test for parametric data and Kruskal-
Wallis test followed by Dunn's multiple comparison test for non-parametric data. *P<0.05, 
**P<0.01, ***P<0.001. Values are presented as mean ± S.E.M. 
Figure 4. Therapeutic nintedanib treatment reduces bleomycin-induced lung inflammation 
and fibrosis. C57Bl/6 mice received an intranasal instillation of NaCl or bleomycin 3 mg/kg. 
Nintedanib was administered qd by gavage at 30 and 60 mg/kg starting at day 7. Analyses 
were performed at day 21. BAL cell differentiation is expressed as cells per mouse lung. A, 
total cell count, B, macrophages, C, lymphocytes. D, interleukin-1 beta (IL-1b), E, chemokine 
(C-X-C motif) ligand 1/keratinocyte chemoattractant (KC), F, tissue inhibitor of 
metalloproteinase-1 (TIMP-1). Total lung collagen was determined by sircol assay in lung 
homogenate (G). Hematoxylin & eosin and chromotrop-anilinblue (CAB) trichrome stained 
slices of the left lung were semi-quantitatively scored for inflammation (H) and fibrosis (I), 
respectively. All groups (n=10 per group except FACS analysis where n=5) were compared 
versus bleomycin-treated control animals by ANOVA followed by Dunnett's multiple 
comparison test for parametric data and Kruskal-Wallis test followed by Dunn's Multiple 
comparison test for non-parametric data. *P<0.05, **P<0.01, ***P<0.001. Values are 
presented as mean ± S.E.M. 
Figure 5. Nintedanib treatment reduces bleomycin-induced lung inflammation and fibrosis. 
Representative micrographs of hematoxylin and eosin-stained lung sections from mice of the 
treatment groups are shown. C57Bl/6 mice that received an intranasal instillation of 
bleomycin 3 mg/kg (B, F) showed a prominent peri-bronchial and interalveolar inflammation 
that was absent in control animals (A, E). Nintedanib was administered qd by gavage at 30 
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(C, G) and 60 mg/kg (D, H). Daily nintedanib treatment from day 0 to day 14 in the preventive 
study (C-D), and from day 7 till day 21 in the therapeutic study (G-H) reduced bleomycin-
induced lung pathology. Analyses were performed on the last day of the study, which was 
day 14 (A-D) or day 21 (E-H). 
Figure 6. Nintedanib treatment reduces bleomycin-induced lung inflammation and fibrosis. 
Representative micrographs of Chromotrope Aniline Blue-stained lung sections from mice of 
the treatment groups are shown. C57Bl/6 mice that received an intranasal instillation of 
bleomycin 3 mg/kg (B, F) showed a prominent peri-brochial and peri-vascular collagen 
accumulation and peri-bronchial and interalveolar inflammation that was absent in control 
animals (A, E). Nintedanib was administered qd by gavage at 30 (C, G) and 60 mg/kg (D, H). 
Daily nintedanib treatment from day 0 to day 14 in the preventive study (C-D), and from day 
7 till day 21 in the therapeutic study (G-H) reduced bleomycin-induced lung pathology. 
Analyses were performed on the last day of the study, which was day 14 (A-D) or day 21 (E-
H).  
Figure 7. Preventive nintedanib treatment reduces silica-induced lung inflammation and 
fibrosis. C57Bl/6 mice received an intranasal instillation of NaCl or silica particles 2.5 
mg/animal. Nintedanib was administered qd by gavage at 30 and 100 mg/kg for 30 days. 
Analyses were performed at day 30. BAL cell differentiation is expressed as cells per mouse 
lung. A, total cell count, B, macrophages, C, lymphocytes, D, neutrophils. Mediator 
concentrations in whole lung homogenates were determined by ELISA. E, interleukin-1 beta 
(IL-1b), F, chemokine (C-X-C motif) ligand 1/keratinocyte chemoattractant (KC), G, tissue 
inhibitor of metalloproteinase-1 (TIMP-1). Total lung collagen was determined by sircol assay 
in lung homogenate (H). Hematoxylin & eosin and chromotrop-anilinblue (CAB) trichrome 
stained slices of the left lung were semi-quantitatively scored for inflammation (I), granuloma 
formation (J) and fibrosis (K). All groups (n=10 per group) were compared versus silica-
treated control animals by ANOVA followed by Dunnett's multiple comparison test for 
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parametric data and Kruskal-Wallis test followed by Dunn's Multiple comparison test for non-
parametric data. *P<0.05, **P<0.01, ***P<0.001. Values are presented as mean ± S.E.M.  
Figure 8. Therapeutic nintedanib treatment reduces silica-induced lung inflammation and 
fibrosis. C57Bl/6 mice received an intranasal instillation of NaCl or silica particles 2.5 
mg/animal. Nintedanib was administered qd by gavage at 30 and 100 mg/kg starting at day 
10 (clear bars) or day 20 (hatched bars). Analyses were performed at day 30. BAL cell 
differentiation is expressed as cells per mouse lung. A, total cell count, B, macrophages, C, 
lymphocytes, D, neutrophils. Mediator concentrations in whole lung homogenates were 
determined by ELISA. E, interleukin-1 beta (IL-1b), F, chemokine (C-X-C motif) ligand 
1/keratinocyte chemoattractant (KC), G, interleukin-6 (IL-6), H, tissue inhibitor of 
metalloproteinase-1 (TIMP-1). Total lung collagen was determined by sircol assay in lung 
homogenate (I). Hematoxylin & eosin and chromotrop-anilinblue (CAB) trichrome stained 
slices of the left lung were semi-quantiatively scored for inflammation (J), granuloma 
formation (K) and fibrosis (L), respectively. All groups (n=10 per group) were compared 
versus silica-treated control animals by ANOVA followed by Dunnett's multiple comparison 
test for parametric data and Kruskal-Wallis test followed by Dunn's Multiple comparison test 






Table 1. Study settings and treatment protocols of the in vivo experiments. 
Table 1  
Study Bleomycin-induced lung fibrosis Silica-induced lung fibrosis 
Posology once daily, oral 
Model preventive therapeutic preventive therapeutic 
Dose [mg/kg] 30, 60 30, 60 30, 100 30, 100 
Study duration 
[days] 












Table 2  
Table 2. Tyrosine kinase inhibition of nintedanib in a cellular BA/F3 assay. 
To compare the cellular activity of nintedanib on specific tyrosine kinase receptors, it was 
tested at 10 nmol/L – 1000 nmol/L in BA/F3 cells engineered to be proliferation-dependent 
on a single tyrosine kinase. IC50 values for nintedanib to inhibit cell proliferation dependent on 
specific tyrosine kinases are listed in nmol/L. 
 
















100 30 10 3 Nintedanib mg/kg 
PDGF-BB i.t. [50 µg]- + + + +
P-PDGFRαβ
(Tyr849/Tyr857)
P-AKT
(Ser473)
P-ERK1/2
(Thr202/Tyr204)
GAPDH
PDGFRα
PDGFRβ
+
- -
60 kDa
40 kDa
40 kDa
220 kDa
120 kDa
120 kDa
120 kDa
Figure 2A
Figure 2B
Figure 3
Figure 4
A B
C D
Figure 5A-D
E F
G H
Figure 5E-H
A B
C D
Figure 6A-D
E F
G H
Figure 6E-H
Figure 7
Figure 8
